Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.78 |
| ▸ | PRSS1 | P07477 | 13/20 | 0.78 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.78 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.78 |
| ▸ | F10 | P00742 | 2/20 | 0.78 |
| ▸ | PLAT | P00750 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4901664 | 0.99 | F2 (0.77) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL3244747 | 0.98 | F2 (0.74) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL14281103 | 0.93 | F2 (0.75) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL3245552 | 0.91 | F2 (0.64) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL6424568 | 0.90 | F2 (0.64) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL3242130 | 0.90 | F2 (0.64) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL14281101 | 0.88 | F2 (0.72) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL14281115 | 0.87 | F2 (0.91) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL4774214 | 0.87 | F2 (1.00) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL4777953 | 0.87 | F2 (0.73) | F2PRSS1PRSS2PRSS3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111870698-B | Thrombin-responsive network polymers and uses thereof | 中国药科大学 | 2022-03-11 | — | — | CN | claimed |
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | claimed |
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | claimed |
| EP-1086122-B1 | PYRAZINONE PROTEASE INHIBITORS | JOHNSON & JOHNSON PHARM RES (US) | 2005-08-24 | — | — | EP | claimed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | claimed |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | LU TIANBAO (US) | 2001-09-13 | — | — | US | claimed |
| US-6204263-B1 | THROMBIN INHIBITORS. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | claimed |
| CN-111870698-B | Thrombin-responsive network polymers and uses thereof | 中国药科大学 | 2022-03-11 | — | — | CN | disclosed |
| US-20180340163-A1 | RECOMBINANT SERINE PROTEASES | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2018-11-29 | — | — | US | disclosed |
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2007146553-A3 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-06 | — | — | WO | disclosed |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | PATEL MITUL N | 2008-01-24 | — | — | US | disclosed |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | PATEL MITUL N | 2008-01-24 | — | — | US | disclosed |
| WO-2007146553-A2 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146553-A2 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1086122-B1 | PYRAZINONE PROTEASE INHIBITORS | JOHNSON & JOHNSON PHARM RES (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | LU TIANBAO (US) | 2001-09-13 | — | — | US | disclosed |
| US-6204263-B1 | THROMBIN INHIBITORS. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | DNPEP, SPINT2, PEPD | F2 154/4885PRSS1 18/4885PRSS2 12/4885 |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | HPN, SERPINE1, SERPINC1 | F2 23/4885PRSS1 10/4885PRSS2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.